TABLE 6.
Preexposure prophylaxis with neutralizing MAbs against challenge of AG129 mice by DENV-3 16652 (gI)c
| MAb | No. of mice that survived | No. of mice that died | Total no. of mice | % Survival | MTDa | ±SD | P valueb |
|---|---|---|---|---|---|---|---|
| DENV-3-E47 | 0 | 7 | 7 | 0 | 15 | 4.4 | >0.1 |
| DENV-3-E48 | 4 | 11 | 21 | 33 | 18 | 8.6 | <0.0005 |
| DENV-3-E49 | 2 | 3 | 5 | 40 | 24 | 5.1 | <0.001 |
| DENV-3-E50 | 9 | 6 | 15 | 60 | 23 | 6.6 | <0.0001 |
| DENV-3-E51 | 1 | 4 | 5 | 20 | 23 | 3.2 | <0.0005 |
| DENV-3-E52 | 0 | 5 | 5 | 0 | 12 | 4.7 | >0.5 |
| DENV-3-E53 | 2 | 3 | 5 | 40 | 22 | 5.9 | <0.001 |
| DENV-3-E54 | 9 | 6 | 15 | 46 | 13 | 9.6 | >0.1 |
| DENV-3-E56 | 2 | 2 | 4 | 50 | 18 | 1.4 | <0.005 |
| DENV-3-E57 | 5 | 3 | 8 | 63 | 23 | 5.0 | <0.0001 |
| DENV-3-E58 | 1 | 3 | 4 | 25 | 18 | 9.2 | <0.05 |
| DENV-3-E59 | 10 | 2 | 12 | 83 | 14 | 4.9 | <0.0001 |
| DENV-3-E60 | 3 | 2 | 5 | 60 | 13 | 8.5 | <0.01 |
| DENV-3-E61 | 8 | 6 | 17 | 47 | 17 | 6.8 | <0.0001 |
| DENV-3-E62 | 2 | 3 | 5 | 40 | 19 | 8.2 | <0.01 |
| DENV-3-E63 | 7 | 2 | 9 | 78 | 10 | 1.4 | <0.005 |
| DENV-3-E64 | 2 | 3 | 5 | 40 | 23 | 2.1 | <0.0005 |
| DENV-3-E67 | 4 | 2 | 6 | 67 | 21 | 2.8 | <0.005 |
| WNV E16 | 1 | 17 | 18 | 6 | 14 | 3.3 |
a
MTD, mean time to death.
b
P values were calculated using the log rank test by comparing values for the negative-control MAb (WNV E16) and antibody-treated mice.
c
Four- to 5-week-old AG129 mice were passively administered 500 μg of the indicated MAbs 1 day before infection with 5 × 103 PFU of strain 16652 by an i.c. route. Mice were monitored for survival for 60 days after infection.